Skip to main content
Premium Trial:

Request an Annual Quote

Jerini s Peptide IP to Help Alcon Develop Drugs for Opthamology

NEW YORK, Jan. 21 (GenomeWeb News) - Jerini has entered into a strategic discovery and development collaboration with Alcon Research to generate new drugs for opthamology.


The companies will employ Jerini's Peptides-to-Drugs discovery platform, including SPOT, pepSPOT, and pepMED, along with other technologies to generate peptidomemetic and small molecule drug candidates and validate their utility for the treatment of eye diseases.


Jerini will receive up-front and license fees, as well as personnel funding, milestone payments, and worldwide royalties on commercial sales of products resulting from the collaboration.


Financial terms of the agreement were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.